GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

England has entered its fourth heat wave of 2025. Historical comparisons for our current weather situation have seemed to ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

A significant burden of neuropsychiatric comorbidities exists among patients with PPD and various psychophysiological disorders.

Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Discover a study validating a disease-specific quality-of-life tool for hidradenitis suppurativa, confirming its reliability, ...

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics’s ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

The study also noted a 15% drop in substance misuse and showed benefit for patients who were taking stimulant medications rather than nonstimulants. Plus: developing new painkillers; how semaglutide ...